June 2017

New Product - Ristempa

Ristempa (pegfilgrastim (rbe)) is a long-acting form of recombinant human granulocyte colony stimulating factor (G-CSF). Ristempa is composed of filgrastim (recombinant methionyl human G-CSF, Neupogen) with a 20,000 dalton polyethylene glycol (PEG) molecule covalently bound to the N-terminal methionine residue. Pegfilgrastim has reduced renal clearance and prolonged persistence in vivo compared to filgrastim. Ristempa is indicated for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropenia and so reduce the incidence of infection, as manifested by febrile neutropenia. Ristempa is contraindicated with known hypersensitivity to Escherichia coli derived proteins, or filgrastim. Ristempa is available as one ready to use prefilled syringe containing 6 mg of pegfilgrastim in 0.6 mL (10 mg/mL).

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au